Approximately 7,248 bottles of Actoplus met XR (pioglitazone and metformin HCl, extended-release) tablets are being recalled because the tablets may be missing the laser-drilled holes required for the metformin core to release medication properly. This defect can prevent the medication from being delivered to the patient as intended. This recall affects 30-count bottles of the 15 mg/1000 mg strength distributed in several U.S. states and Puerto Rico.
The missing or partial laser-drilled holes on the tablet core can lead to an ineffective delivery of the medication, which may result in poor blood sugar control for patients with type 2 diabetes.
Pharmacy refund and healthcare consultation
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.